TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) Net income 2016–2025
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$124.0MFY2025 · since FY2016: -$38.8M → -$124.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$124.0M | +4.6% |
| FY2024 | -$130.0M | -11.5% |
| FY2023 | -$116.7M | -5.8% |
| FY2022 | -$110.2M | -19.4% |
| FY2021 | -$92.3M | -82.9% |
| FY2020 | -$50.5M | -76.3% |
| FY2019 | -$28.6M | -9.7% |
| FY2018 | -$26.1M | -23.5% |
| FY2017 | -$21.1M | +45.6% |
| FY2016 | -$38.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More TNXP financial trends
TNXP RevenueTNXP Net marginTNXP Gross profitTNXP Gross marginTNXP Operating incomeTNXP Operating marginTNXP Operating cash flowTNXP Free cash flowTNXP Capital expendituresTNXP Return on equityTNXP Stock buybacksTNXP Dividends paidTNXP Total assetsTNXP Total liabilitiesTNXP Shareholders’ equityTNXP overview →